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1  Aim
The aim of this chapter is to explain why Neurofilaments (Nf) are a useful biomarker for axonal 
degeneration and can be used as a surrogate endpoint in clinical and experimental research.  
2  Definitions
 Neurofilaments:     Nf are proteins which are exclusively expressed in neurons and their 
adjacent axons. Nf are particularly abundant in the axon, where they are key building 
blocks of the axonal cytoskeleton. The complex protein chemistry of Nf is briefly 
described. 
 Biomarker:     A biomarker is a characteristic that is objectively measured and evaluated as 
an indicator of normal biologic processes, pathogenic processes, or pharmacological 
responses to therapeutic intervention.
 Surrogate endpoint    : defines a biomarker that is intended to serve as a substitute of a 
clinically meaningful endpoint and is expected to predict the effect of a therapeutic 
intervention or the evolution of disease. 
2  Quantitative description
Nf are obligate heteropolymers that are composed of 4 subunits: a light (NfL), a medium (NfM), 
a heavy (NfH) [1] chain and also alpha-internexin [2, 3]. In some cases, peripherin may be 
added to the list [2]. These subunits differ not only in their molecular weight, but also in their 
functional properties, as discussed below.
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 The Nf light chain (NfL) is coded on chromosome 8p21 and consists of 543 amino acids. The 
molecular mass corresponds to 61 kDa, but due to phosphorylation and glycosylation, migration 
in sodium dodecyl sulfate (SDS) polyacrylamide gels (PAGE) is slow, and most authors refer to 
a molecular mass of 68 kDa as determined in SDS–PAGE. NfL forms the back-bone of the Nf 
heteropolymer and can self–assemble. Mutations in the NfL gene have been associated with 
Charcot-Marie Tooth disease.
NfM
 The Nf medium chain (NfM) is also coded on chromosome 8p21 and consists of 916 amino 
acids. The molecular mass is calculated as 102.5 kDa, and runs at 150 kDa in SDS gels. NfM is 
important for the radial axonal growth. One mutation in the NfM gene has been associated with 
Parkinsons disease.
NfH
 The Nf heavy chain (NfH) is coded on chromosome 22q12.2 and consists of 1020 amino acids. 
The molecular mass of the amino acids corresponds to 111 kDa. Most authors however refer to 
the molecular mass derived from SDS gels which is also influenced by the charge/weight of 
bound phosphate and therefore ranges from 190 to 210 kDa for the various phosphoforms. NfH 
is   important   for   protein-protein   interactions   which   is   regulated   locally   in   the   axon   by 
phosphorylation. Mutations in the NfH gene have been associated with Amyotrophic lateral 
sclerosis (ALS).
Alpha-internexin
  The 66 kDa alpha-internexin protein is coded on chromosome 10q24.33 and able to form 
homopolymers.  Alpha-internexin has only recently been rediscovered as one of the Nf subunits 
and its role of  alpha-internexin is still poorly understood [3]. Extracellular deposists of alpha-
internexin are an important hallmark of a newly discovered neurodegenerative dementia named 
neurofilament inclusion disease (NFID).
Assembly of the Nf heteropolymer
 Figure 1 illustrated how NfL, NfM and NfH assemble to produce the Nf heteropolymer, which 
has a diameter of about 10 nm. Because of its size, which is intermediate between the smaller 
proteins, e.g. microfilaments (7 nm) and larger proteins such as microtubules (approximately 25 
nm), the Nf heteropolymer  belongs to the intermediate filaments.
Stoichiometry of the Nf subunits
 The estimated in vitro molar ratio of isolated Nfs from the mouse optic nerve and spinal cord is 
4:2:2:1 (NfL:a–internexin:NfM:NfH) [3]. The in vivo stoichiometry of Nfs in body fluids remains 
unknown.Classification of Nf
 Nf are type IV intermediate filaments (Table 1).
3  Nf are a biomarker for axonal degeneration
Nf subunits are useful biomarkers for axonal degeneration, as illustrated in Figure 2. Any insult 
causing neuronal death or axonal degeneration will inevitably result in disintegration of the 
axonal membrane. Subsequently the contents of the axonal cytoplasm are released into the 
extracellular fluid (ECF). From the ECF Nfs diffuse into other body fluid compartments such as 
the cerebrospinal fluid (CSF), blood or amniotic fluid. As explained above Nf are a major 
structural protein component of the axon and the quantification of Nfs from body fluids therefore 
allows estimation of the degree of axonal degeneration.
3.1  The measurement of Nf body fluid levels
At present, high–throughput quantification of Nfs from body fluids and tissue homogenates is 
best achieved using enzyme linked immune assays (ELISA). In-house ELISAs have been 
developed for NfL and NfH [4, 5, 6, 7]. These assays are highly robust and have been cross–
validated [8, 9]. A commercial NfH ELISA kit has recently been made available (Chemicon). 
Alternatively immunoblots or dot–blot assays have been used, but generally they are not high–
throughput and only semi–quantitative.
3.2  The diseases associated with high body fluid Nf levels
Neuronal loss and axonal degeneration are a key feature in numerous disorders and frequently 
represent the endstage of a pathophysiological cascade. Not surprisingly, body fluid levels of Nf 
subunits have been used to estimate the degree of axonal damage in a number of diseases 
(Table 2). It is important to remember that body fluid Nf levels are not a diagnostic test for one 
single disease. In contrast Nf are a biomarker and surrogate enpoint according to the initial 
definitions.
4 Conclusion
Neurofilaments are complex proteins composed of four subunits, expressed exclusively in the 
neuro-axonal compartment. Nf are released into the extracellular fluid from degenerating axons. 
From the extracellular fluid they diffuse into adjacent body fluid compartments. Using standard 
ELISA techniques Nf subunits have been quantified from the cerebrospinal fluid, the blood and 
the amniotic fluid. Because body fluid levels of Nf are related to the amount of neuronal death 
and axonal loss, they provide valuable prognostic information and correlate with disability in a 
number of diseases.5 Acknowledgements
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6 Glossary
Neurofilament (Nf)
 Obligate polymer consisting of four proteins: a–internexin, the neurofilament light (NfL), medium 
(NfM) and heavy (NfH) chains. Nf are a structural constituent of the neuronal and axonal 
cytoskeleton.
Alpha–internexin
 A 66 kDa protein encoded on chromosome 10q24.33.
Neurofilament light chain (NfL)
 A 68 kDa protein encoded on chromosome 8p21.
Neurofilament medium chain(NfM)
 A 150 kDa protein encoded on chromosome 8p21.
Neurofilament heavy chain(NfH)
  A  190  to  210  kDa   protein  depending  on  the  degree  of  phosphorylation,   encoded  on 
chromosome 22q12.2.
Axonal degeneration
  There are two types: (1) Wallerian degeneration occurs distal to a lesion and effectively 
removes the damaged axon; (2) dying back neuropathy occurs proximal to the lesion and 
ultimately causes apoptosis of the neuron.
Biomarker
 A characteristic that is objectively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacological responses to therapeutic intervention.
Surrogate outcome
 A biomarker that is used as an outcome measure in e.g. a clinical trial. Surrogate outcomes are 
powerful tools increasingly used in large, multi-center trials.Cerebrospinal fluid (CSF)
The fluid surrounding the brain and spinal cord. In humans approximately 150 to 250 mL of CSF 
fill the ventricles and subarachnoid space all the way down into the lumbar sac. The CSF 
consists to 99% of water and has a  much lower protein concentration (approximately 350 mg/L) 
than the serum (70,000 g/L). Of these proteins only about 10% originate from the ECF drained 
form the CNS parenchyma. These may be called “brain specific proteins” and are of particular 
interest for biomarker research.
Extracellular fluid (ECF)
 The extracellular or interstitial fluid surrounds the cells and is a component of the extracellular 
matrix.
Polymer
 A compound consisting of many repeated linked units. 
 Figure 1:  Neurofilament assembly. The central rod domain of the Nf subunits is intertwined in 
order to form dimers. The dimers are arranged antiparallel to form tetramers. Tetramers 
combine to form protofilaments, which finally assemble to produce the 10 nm thick Nf (Figure 
reprinted with permission from reference [10]). 
 Figure 2:  Neurofilaments are released into the extracellular fluid (ECF) following axonal 
disintegration. From the ECF Nfs equilibrate with the adjacent body fluid compartment. 
Quantification of Nfs is therefore possible from the cerebrospinal fluid (CSF), blood and 
amniotic fluid. The degree of axonal degeneration is related to the amount of Nf measured in 
these body fluids. For this reason body fluid Nf levels permit to estimate the amount of axonal 
degeneration. Axonal degeneration is extremely important because the loss of axons is 
irreversible and may therefore lead to persistent disability. Table 1:  Classification of intermediate filaments and cell-type 
specificity. GFAP = glial fibrillary acidic protein.
Class Identity Cell–type 
specificity
Type I Acidic keratins Epithelial
Type II Neutral & Basic 
keratins
Epithelial





Type IV NfL, NfM, NfH Neuron & Axon
Alpha-Internexin Neuron & Axon
Type V Laminin A, B, C Most cells
Type VI Nestin CNS stem cells
 Table 2:  Diseases in which Nf have been used as a body fluid biomarker for neuronal death 
and axonal degeneration. AD = Alzheimer’s disease, ALS = amyotrophic lateral sclerosis, 
CBD = cortico–basal degeneration, DLB = Diffuse Lewy body disease, FTLD = fronto–
temporal lobar degeneration, GBS = Guillain–Barré syndrome, ICH = intracerebral 
haemorrhage, MMC = meningo–myelocele, MS = multiple sclerosis, MSA = multiple system 
atrophy, NMO = neuromyelitis optica, ON = optic neuritis, PD = Parkinson’s disease, PSP = 
progressive supranuclear palsy, SAH = subarachnoid haemorrhage. 
Disease Findings
 AD CSF NfL and NfH levels are elevated in AD. The difference from controls was marginal for CSF 
NfH levels and more impressive for NfL levels.
ALS CSF NfL and NfH levels are considerably increased in patients with ALS. Rapidly progressing 
ALS patients had the highest CSF NfH levels.
CBD CSF NfL and NfH levels are elevated in patients with CBD.
FTLD CSF NfL is elevated and CSF NfH marginally elevated in patients with FLTD. The degree of NfH 
phosphorylation is increased in FTLD compared to AD and controls.
GBS Elevated CSF NfH levels in patients with GBS are a poor prognostic sign, probably due to 
proximal axonal degeneration. Proximal axonal degeneration at the level of the nerve roots 
rapidly releases Nfs into the CSF. Proximal axonotmesis requires axonal regrowth over a long 
distance with the risk of losing chemical and anatomical guidance cues.
ICH CSF NfH levels are high in ICH, probably indicating direct axonal degeneration due to rupture 
and ischemia.
DLB CSF NfH but not NfL levels are elevated in DLB compared to AD and controls.
MMC Amniotic fluid NfH levels are elevated in mice with MMC and correlated with the size of the 
lesion.
MS CSF NfH and NfL levels are elevated in MS. CSF NfL levels are highest following a clinical 
relapse and return to baseline within about 3 months. CSF NfH levels are highest in the 
secondary progressive phase of the disease when axonal degeneration accumulates. The 
degree of NfH phosphorylation is increased in patient with more severe disease. High CSF NfH 
levels are a poor prognostic sign. Both CSF NfL and NfH levels correlate with disability.
MSA CSF NfL and NfH levels are markedly elevated in MSA compared to controls and patients with 
PD. This may be related to the greater degree and more rapid disease progression in MSA. The 
highest levels are found in patients with the cerebellar variant of MSA, which may be of help for 
the differential diagnosis of patients with cerebellar syndromes.
NMO CSF NfH levels are considerably elevated in NMO (synonymousDevic's disease) suggesting that 
these patients suffer from substantially more axonal damage than patients with MS or ON.
ON Plasma NfH levels are increased in acute ON. CSF NfH levels were elevated in patients with 
subacute ON. Plasma and CSF NfH levels correlated with loss of visual function.
PD CSF NfH and NfL levels are increased in PD compared to controls.
PSP CSF NfL and NfH levels are elevated in PSP compared to controls and patients with PD. As with 
MSA this may be related to the greater degree of axonal loss and more rapid disease 
progression in PSP patients, who are also very resistant to pharmacological treatment.
SAH CSF NfL and NfH levels are elevated in SAH and correlated with the outcome. Importantly CSF 
NfH levels showed a secondary increase during the high risk period of vasospasm, probably 
indicating secondary axonal degeneration following an ischemic insult.
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